These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

452 related articles for article (PubMed ID: 15558802)

  • 1. Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma.
    Reardon DA; Quinn JA; Vredenburgh J; Rich JN; Gururangan S; Badruddoja M; Herndon JE; Dowell JM; Friedman AH; Friedman HS
    Cancer; 2005 Jan; 103(2):329-38. PubMed ID: 15558802
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma.
    Reardon DA; Quinn JA; Rich JN; Desjardins A; Vredenburgh J; Gururangan S; Sathornsumetee S; Badruddoja M; McLendon R; Provenzale J; Herndon JE; Dowell JM; Burkart JL; Newton HB; Friedman AH; Friedman HS
    Cancer; 2005 Oct; 104(7):1478-86. PubMed ID: 16088964
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Two studies evaluating irinotecan treatment for recurrent malignant glioma using an every-3-week regimen.
    Cloughesy TF; Filka E; Kuhn J; Nelson G; Kabbinavar F; Friedman H; Miller LL; Elfring GL
    Cancer; 2003 May; 97(9 Suppl):2381-6. PubMed ID: 12712460
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study.
    Prados MD; Lamborn K; Yung WK; Jaeckle K; Robins HI; Mehta M; Fine HA; Wen PY; Cloughesy T; Chang S; Nicholas MK; Schiff D; Greenberg H; Junck L; Fink K; Hess K; Kuhn J;
    Neuro Oncol; 2006 Apr; 8(2):189-93. PubMed ID: 16533878
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults.
    Kesari S; Schiff D; Doherty L; Gigas DC; Batchelor TT; Muzikansky A; O'Neill A; Drappatz J; Chen-Plotkin AS; Ramakrishna N; Weiss SE; Levy B; Bradshaw J; Kracher J; Laforme A; Black PM; Folkman J; Kieran M; Wen PY
    Neuro Oncol; 2007 Jul; 9(3):354-63. PubMed ID: 17452651
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase 1 trial of irinotecan plus BCNU in patients with progressive or recurrent malignant glioma.
    Quinn JA; Reardon DA; Friedman AH; Rich JN; Sampson JH; Vredenburgh J; Gururangan S; Provenzale JM; Walker A; Schweitzer H; Bigner DD; Tourt-Uhlig S; Herndon JE; Affronti ML; Jackson S; Allen D; Ziegler K; Bohlin C; Lentz C; Friedman HS
    Neuro Oncol; 2004 Apr; 6(2):145-53. PubMed ID: 15134629
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas.
    Desjardins A; Reardon DA; Herndon JE; Marcello J; Quinn JA; Rich JN; Sathornsumetee S; Gururangan S; Sampson J; Bailey L; Bigner DD; Friedman AH; Friedman HS; Vredenburgh JJ
    Clin Cancer Res; 2008 Nov; 14(21):7068-73. PubMed ID: 18981004
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).
    Brandes AA; Tosoni A; Basso U; Reni M; Valduga F; Monfardini S; Amistà P; Nicolardi L; Sotti G; Ermani M
    J Clin Oncol; 2004 Dec; 22(23):4779-86. PubMed ID: 15570079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase 2 trial of BCNU plus irinotecan in adults with malignant glioma.
    Reardon DA; Quinn JA; Rich JN; Gururangan S; Vredenburgh J; Sampson JH; Provenzale JM; Walker A; Badruddoja M; Tourt-Uhlig S; Herndon JE; Dowell JM; Affronti ML; Jackson S; Allen D; Ziegler K; Silverman S; Bohlin C; Friedman AH; Bigner DD; Friedman HS
    Neuro Oncol; 2004 Apr; 6(2):134-44. PubMed ID: 15134628
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase 1 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study.
    Prados MD; Yung WK; Jaeckle KA; Robins HI; Mehta MP; Fine HA; Wen PY; Cloughesy TF; Chang SM; Nicholas MK; Schiff D; Greenberg HS; Junck L; Fink KL; Hess KR; Kuhn J;
    Neuro Oncol; 2004 Jan; 6(1):44-54. PubMed ID: 14769140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I trial of tipifarnib in patients with recurrent malignant glioma taking enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study.
    Cloughesy TF; Kuhn J; Robins HI; Abrey L; Wen P; Fink K; Lieberman FS; Mehta M; Chang S; Yung A; DeAngelis L; Schiff D; Junck L; Groves M; Paquette S; Wright J; Lamborn K; Sebti SM; Prados M
    J Clin Oncol; 2005 Sep; 23(27):6647-56. PubMed ID: 16170172
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study.
    Cloughesy TF; Wen PY; Robins HI; Chang SM; Groves MD; Fink KL; Junck L; Schiff D; Abrey L; Gilbert MR; Lieberman F; Kuhn J; DeAngelis LM; Mehta M; Raizer JJ; Yung WK; Aldape K; Wright J; Lamborn KR; Prados MD
    J Clin Oncol; 2006 Aug; 24(22):3651-6. PubMed ID: 16877733
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase 1 trial of temozolomide plus irinotecan plus O6-benzylguanine in adults with recurrent malignant glioma.
    Quinn JA; Jiang SX; Reardon DA; Desjardins A; Vredenburgh JJ; Gururangan S; Sampson JH; McLendon RE; Herndon JE; Friedman HS
    Cancer; 2009 Jul; 115(13):2964-70. PubMed ID: 19402172
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma.
    Vredenburgh JJ; Desjardins A; Herndon JE; Dowell JM; Reardon DA; Quinn JA; Rich JN; Sathornsumetee S; Gururangan S; Wagner M; Bigner DD; Friedman AH; Friedman HS
    Clin Cancer Res; 2007 Feb; 13(4):1253-9. PubMed ID: 17317837
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Temozolomide in the treatment of recurrent malignant glioma.
    Chang SM; Theodosopoulos P; Lamborn K; Malec M; Rabbitt J; Page M; Prados MD
    Cancer; 2004 Feb; 100(3):605-11. PubMed ID: 14745879
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I study of temozolomide and irinotecan for recurrent malignant gliomas in patients receiving enzyme-inducing antiepileptic drugs: a north american brain tumor consortium study.
    Loghin ME; Prados MD; Wen P; Junck L; Lieberman F; Fine H; Fink KL; Metha M; Kuhn J; Lamborn K; Chang SM; Cloughesy T; DeAngelis LM; Robins IH; Aldape KD; Yung WK
    Clin Cancer Res; 2007 Dec; 13(23):7133-8. PubMed ID: 18056194
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bevacizumab plus irinotecan in the treatment patients with progressive recurrent malignant brain tumours.
    Poulsen HS; Grunnet K; Sorensen M; Olsen P; Hasselbalch B; Nelausen K; Kosteljanetz M; Lassen U
    Acta Oncol; 2009; 48(1):52-8. PubMed ID: 19031176
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II trial of two different irinotecan schedules with pharmacokinetic analysis in patients with recurrent glioma: North Central Cancer Treatment Group results.
    Santisteban M; Buckner JC; Reid JM; Wu W; Scheithauer BW; Ames MM; Felten SJ; Nikcevich DA; Wiesenfeld M; Jaeckle KA; Galanis E;
    J Neurooncol; 2009 Apr; 92(2):165-75. PubMed ID: 19066728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase 2 study of weekly irinotecan in adults with recurrent malignant glioma: final report of NABTT 97-11.
    Batchelor TT; Gilbert MR; Supko JG; Carson KA; Nabors LB; Grossman SA; Lesser GJ; Mikkelsen T; Phuphanich S;
    Neuro Oncol; 2004 Jan; 6(1):21-7. PubMed ID: 14769136
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study of irinotecan (CPT-11) in children with high-risk malignant brain tumors: the Duke experience.
    Turner CD; Gururangan S; Eastwood J; Bottom K; Watral M; Beason R; McLendon RE; Friedman AH; Tourt-Uhlig S; Miller LL; Friedman HS
    Neuro Oncol; 2002 Apr; 4(2):102-8. PubMed ID: 11916501
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.